Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
Neeltje van Doremalen, Jyothi N. Purushotham, Jonathan E. Schulz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Vivek P. Chavda, Lalitkumar K. Vora, Anjali Pandya, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2619-2636
Open Access | Times Cited: 188
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
Dennis Lapuente, Jana Fuchs, Jonas Willar, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 183
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Alexandra J. Spencer, Paul F. McKay, Sandra Belij‐Rammerstorfer, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 125
Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
R. Glenn King, Aarón Silva-Sánchez, Jessica N. Peel, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 881-881
Open Access | Times Cited: 109
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Mattia Tiboni, Luca Casettari, Lisbeth Illum
International Journal of Pharmaceutics (2021) Vol. 603, pp. 120686-120686
Open Access | Times Cited: 105
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
Kuldeep Dhama, Manish Dhawan, Ruchi Tiwari, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 75
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
Vivek P. Chavda, Rajashri Bezbaruah, Disha Valu, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 432-432
Open Access | Times Cited: 49
Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
Anna K. Blakney, Paul F. McKay, Kai Hu, et al.
Journal of Controlled Release (2021) Vol. 338, pp. 201-210
Open Access | Times Cited: 89
Intranasal vaccine: Factors to consider in research and development
Haiyue Xu, Lucy Cai, Stephanie Hufnagel, et al.
International Journal of Pharmaceutics (2021) Vol. 609, pp. 121180-121180
Closed Access | Times Cited: 68
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
Robert J. Fischer, Neeltje van Doremalen, Danielle R. Adney, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 65
COVID-19 Vaccines: Adenoviral Vectors
Catherine Jacob-Dolan, Dan H. Barouch
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 41-54
Open Access | Times Cited: 60
Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection
Basanth Babu Eedara, Wafaa Alabsi, David Encinas-Basurto, et al.
Pharmaceutics (2021) Vol. 13, Iss. 7, pp. 1077-1077
Open Access | Times Cited: 56
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Violette Mouro, Alain Fischer
Mucosal Immunology (2022) Vol. 15, Iss. 4, pp. 584-594
Open Access | Times Cited: 51
Advances in intranasal vaccine delivery: A promising non-invasive route of immunization
Eleni Kehagia, Paraskevi Papakyriakopoulou, Georgia Valsami
Vaccine (2023) Vol. 41, Iss. 24, pp. 3589-3603
Open Access | Times Cited: 37
Delivery Routes for COVID-19 Vaccines
Jang Hyun Park, Heung Kyu Lee
Vaccines (2021) Vol. 9, Iss. 5, pp. 524-524
Open Access | Times Cited: 54
Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces
Hang Fai Kwok
International Journal of Biological Sciences (2021) Vol. 17, Iss. 6, pp. 1461-1468
Open Access | Times Cited: 47
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
Neeltje van Doremalen, Jonathan E. Schulz, Danielle R. Adney, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Jie Tang, Larry Cai, Chuanfei Xu, et al.
Nanomaterials (2022) Vol. 12, Iss. 2, pp. 226-226
Open Access | Times Cited: 35
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern
David W. Hawman, Kimberly Meade‐White, Jacob Archer, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 32
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Pedro M. Folegatti, Daniel Jenkin, Susan Morris, et al.
Vaccine (2022) Vol. 40, Iss. 35, pp. 5248-5262
Open Access | Times Cited: 28
Animal models of SARS-CoV-2 transmission
Rory D. de Vries, Barry Rockx, Bart L. Haagmans, et al.
Current Opinion in Virology (2021) Vol. 50, pp. 8-16
Open Access | Times Cited: 36
A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
Paul E. Harris, Trevor Brasel, Christopher Massey, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 520-520
Open Access | Times Cited: 34
A spatial multi-omics atlas of the human lung reveals a novel immune cell survival niche
Elo Madissoon, Amanda J. Oliver, Vitalii Kleshchevnikov, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 34
A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine
Jingen Zhu, Swati Jain, Jian Sha, et al.
mBio (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 25
Intranasal administration of a virus like particles‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern
Dominik A. Rothen, Pascal S. Krenger, Aleksandra Nonic, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2446-2458
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top